Johnson & Johnson Stock Price Soars, But Valuation Models Indicate Significant Overvaluation
Johnson & Johnson (JNJ) has seen its stock price surge by 58.5% over the past year, but despite this impressive performance, our DCF analysis indicates that the company is significantly overvalued. According to the earnings-based model, JNJ's intrinsic value stands at $123.97, while its current market price is $269.99, revealing a margin of safety of -117.8%. The free cash flow (FCF)-based model yields an even lower intrinsic value of $105.26, further reinforcing the conclusion that investors should exercise caution.
The GuruFocus Value (GF Value) for JNJ is $193.54, providing another perspective on the valuation. However, all three models, DCF earnings, DCF FCF, and GF Value, agree that JNJ is overvalued, which adds to the weight of the analysis.
JNJ's strong fundamentals are reflected in its GF Score of 80/100, but its predictability rank of 0/5 stars suggests that the DCF model's reliability is limited. The company's financial strength and profitability metrics are also impressive, with ratings of 7/10 and 9/10 respectively.